XML 24 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Product and Geographic Information
 3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Product and Geographic Information Product and Geographic Information
Revenues of the Company’s products were as follows:
Three Months Ended March 31,
20252024
($ in millions)U.S.Int’lTotalU.S.Int’lTotal
Women’s Health
Nexplanon/Implanon NXT$176 $72 $248 $153 $67 $220 
Follistim AQ35 34 69 11 35 46 
NuvaRing
6 16 22 16 22 38 
Ganirelix Acetate Injection
5 23 27 6 23 29 
Marvelon/Mercilon
— 39 39 — 33 33 
Jada15 — 15 13 — 13 
Other Women’s Health (1)
15 27 43 15 28 43 
Biosimilars
Renflexis44 12 57 55 14 69 
Hadlima33 14 47 22 8 30 
Ontruzant4 14 18 8 31 39 
Brenzys— 14 14 — 24 24 
Aybintio— 5 5 — 8 8 
Established Brands
Cardiovascular
Atozet— 77 77 — 132 132 
Zetia1 84 85 2 82 84 
Cozaar/Hyzaar2 53 55 3 65 67 
Vytorin1 22 23 1 27 28 
Rosuzet— 4 4 — 16 16 
Other Cardiovascular (1)
— 30 30 — 37 38 
Respiratory
Singulair2 72 74 2 95 98 
Nasonex— 71 72 — 77 77 
Dulera34 10 43 43 13 56 
Clarinex— 34 34 1 36 37 
Other Respiratory (1)
10 3 13 7 3 9 
Non-Opioid Pain, Bone and Dermatology
Arcoxia— 62 62 — 75 75 
Fosamax1 32 33 1 38 40 
Diprospan— 30 30 — 29 29 
Vtama
20 4 24 — — — 
Other Non-Opioid Pain, Bone and Dermatology (1)
4 65 68 5 68 72 
Other
Propecia1 24 26 2 21 23 
Emgality/Rayvow
— 32 32 — 10 10 
Proscar— 24 24 — 26 26 
Other (1)
3 76 78 5 79 84 
Other (2)
— 22 22 — 29 29 
Revenues$412 $1,101 $1,513 $371 $1,251 $1,622 
Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately.
(2) Includes manufacturing sales to third parties.
Revenues by geographic area where derived are as follows:
Three Months Ended
March 31,
($ in millions)20252024
Europe and Canada$376 $450 
United States412 371 
Asia Pacific and Japan251 287 
China204 206 
Latin America, Middle East, Russia, and Africa
240 274 
Other (1)
30 34 
Revenues$1,513 $1,622 
(1) Includes manufacturing sales to third parties.